Research Article

Cardioprotective Effects of Solidago microglossa DC. in Nicotine-Treated Hypertensive Rats

Table 6

Effects of oral treatment with Solidago microglossa extract (EESM) and hydrochlorothiazide (HCTZ) on mesenteric arterial reactivity.

ParameterNaïveNCHCTZEESM (14 mg/kg)EESM (28 mg/kg)EESM (56 mg/kg)

Phe (nmol)
12.69 ± 0.555.01 ± 1.34a3.62 ± 1.02bcd8.96 ± 3.12a8.91 ± 2.76a3.41 ± 0.76bcd
33.41 ± 0.686.43 ± 1.49a4.87 ± 1.13bcd13.24 ± 3.28a34.52 ± 7.61a4.56 ± 0.88bcd
1017.36 ± 8.1265.24 ± 19.10a29.04 ± 12.11bcd59.65 ± 16.96a54.84 ± 50.31a22.04 ± 7.11bcd
3073.62 ± 9.98156.61 ± 23.76a87.64 ± 9.63bcd184.30 ± 20.20a146.50 ± 29.38a82.33 ± 8.51bcd

ACh (pmol)
10−10.81 ± 3.39−5.84 ± 2.93a−13.56 ± 3.64bcd−7.73 ± 2.57a6.67 ± 1.67a−14.21 ± 3.01bcd
30−19.78 ± 3.09−9.03 ± 2.67a−17.15 ± 2.98bcd−9.00 ± 3.84a−10.38 ± 2.01a−18.11 ± 2.44bcd
100−23.52 ± 4.76−12.89 ± 3.73a−20.78 ± 3.95bcd−12.54 ± 3.67a−13.51 ± 3.25a−23.43 ± 3.74bcd
300−35.65 ± 5.46−12.74 ± 3.76a−30.83 ± 6.89bcd−10.39 ± 3.82a−13.31 ± 4.33a−37.77 ± 7.21bcd

SNP (pmol)
10−4.11 ± 1.40−5.25 ± 2.89−5.53 ± 2.95−6.20 ± 2.52−5.57 ± 1.62−5.11 ± 1.56
30−6.57 ± 6.73−6.43 ± 1.62−7.89 ± 3.62−7.87 ± 3.32−8.97 ± 2.79−6.88 ± 2.51
100−8.01 ± 2.14−7.00 ± 2.10−9.53 ± 3.91−8.75 ± 3.31−10.13 ± 2.51−9.99 ± 2.76
300−17.64 ± 2.48−15.99 ± 2.59−16.34 ± 3.01−17.56 ± 3.43−18.12 ± 3.58−16.34 ± 3.43

Statistical analyses were performed using one-way ANOVA followed by Tukey’s test. Values are expressed as mean ± SEM (standard error of the mean) of 8 animals per group. a when compared to the naïve rats. b when compared to the NC group. c when compared to the EESM 14 mg/kg. d when compared to the EESM 28 mg/kg. EESM: hypertensive rats that received three different doses of the Solidago microglossa extract; HCTZ: hypertensive animals that received daily doses of hydrochlorothiazide (25 mg/kg); NC: hypertensive animals that received daily doses of the vehicle; Naïve: normotensive animals that received only the vehicle. ACh: acetylcholine; Phe: phenylephrine; SNP: sodium nitroprusside.